{"groups":[{"description":"mifepristone at doses from 300 mg/day up to 1200 mg/day daily","id":"FG000","title":"Open-label"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Only subjects who had completed C1073-400 (NCT00569582) were enrolled. All subjects received active drug (no placebo).","recruitmentDetails":"Subjects completing 24 weeks of mifepristone treatment under Corcept protocol C1073-400 (NCT00569582) were eligible to continue treatment in C1073-415 at the dose being administered at the end of treatment in C1073-400 (NCT00569582)."}